Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry AMD Trial

Published: Tuesday, June 24, 2014
Last Updated: Tuesday, June 24, 2014
Bookmark and Share
Phase II clinical trial to begin this year.

StemCells, Inc. has announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year.

Interim results for the current AMD trial show a 70 percent reduction in the rate of geographic atrophy (GA) as compared to the control eye and a 65 percent reduction in the rate of GA as compared to the expected natural history of the disease following a single dose of the Company's proprietary HuCNS-SC® human neural stem cells.

In addition to these initial efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile for HuCNS-SC® as a treatment for dry AMD. Final results from this landmark study are expected to be released mid-2015.

"The strength of the interim results exceeded our expectations," said Stephen Huhn, M.D., FACS, FAAP, vice president, CNS clinical research and chief medical officer, StemCells, Inc. "These positive clinical safety and efficacy findings are an important milestone in our goal of developing a first-in-class therapy for dry AMD based on our proprietary HuCNS-SC platform technology. We now need to move forward to the next phase of product development and replicate these results in a Phase II study appropriately designed to demonstrate the efficacy of our HuCNS-SC cells as a treatment for dry AMD."

"There is a large unmet medical need for patients suffering from this disabling disease," continued Dr. Huhn. "I have the utmost respect and gratitude for all of the brave patients, their families and caregivers who have been open to participating in this study."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

StemCells, Inc. Appoints Dr. Alan Trounson
Company announces appointment of Dr. Trounson to its Board of Directors.
Thursday, July 10, 2014
StemCells, Inc. Strengthens Senior Executive Team
Company appoints Joel Naor, Naymisha Patel and Mohammad A. El-Kalay and promote Stephen Huhn to the position of vice president.
Thursday, June 19, 2014
StemCells Inc. Advances Clinical Trial in AMD to Final Cohort
Phase I/II AMD trial on track to complete enrollment in June.
Saturday, May 24, 2014
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
Mr. Schiffman will join Company’s executive team, effective January 1, 2014.
Friday, November 15, 2013
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision
HuCNS-SC(R) cells (purified human neural stem cells) found to protect host photoreceptors and preserve vision in an animal model of retinal disease.
Monday, January 30, 2012
StemCells, Inc. Announces Closing of Public Offering of Common Stock and Warrants
The company announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit.
Friday, December 23, 2011
Stemcells, Inc. To Present At 2011 Stem Cell Meeting
StemCells, Inc. have announced that Martin McGlynn, President and CEO, will present a business update at the 2011 Forum.
Tuesday, November 29, 2011
World’s First Neural Stem Cell Transplant in Spinal Cord Injury Patient
The transplant surgery was performed by a team of surgeons led by Dr. Raphael Guzman and Dr. K. Min.
Monday, September 26, 2011
Stemcells, Inc. Awarded CIRM Planning Grant to Pursue Preclinical Development of HuCNS-SC Cells for Alzheimer’s Disease
CIRM has approved the Company’s application for a “Disease Team Therapy Development Planning Award.”
Friday, September 02, 2011
StemCells Regains Compliance for Continued NASDAQ Global Market Listing
Company has received notification from The NASDAQ stock market that the Company has regained compliance with the minimum bid price requirement.
Friday, July 22, 2011
Stemcells, Inc. Relocates Corporate Headquarters and U.S. Research Labs
Corporate headquarters and U.S.-based research and development operations relocate to 7707 Gateway Blvd, Newark, CA 94560, USA.
Wednesday, July 20, 2011
Stemcells to Present Clinical Evidence of Long-term Survival of HuCNS-SC® Cells Following Completion of Immunosuppression Regimen
The data will be reported at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, June 15-18 in Toronto, Ontario.
Thursday, June 16, 2011
StemCells, Inc. Reports First Quarter Financial Results and Announces Reduction in Force
Company to reduce US-based workforce by 30 percent to reduce its cash burn rate and extends financial resources to focus on advancing the clinical development of HuCNS-SC® cells.
Friday, May 06, 2011
Scientific News
Crucial for Stem Cell Survival Protein Identified Using Editing Tool CRISPR
A team of University of Wisconsin-Madison engineers has identified a protein that is integral to the survival and self-renewal processes of human pluripotent stem cells (hPSC).
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!